Initiation of adaptive immune responses by transcutaneous immunization

Immunology Letters

Volumn 109, Issue 1, 2007, Pages 13-20

  Warger, Tobias ^a   Schild, Hansjörg ^a   Rechtsteiner, Gerd ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Adjuvant; Antigen; Cholera toxin; Epidermis; Heat labile enterotoxin (LT); Imiquimod; Skin; Skin associated lymphoid tissue; Toll like receptor ligand; Transcutaneous immunization; Vaccination

Indexed keywords

ALUMINUM HYDROXIDE; CHOLERA TOXIN; CHOLERA TOXIN A SUBUNIT; CHOLERA TOXIN B SUBUNIT; CPG OLIGODEOXYNUCLEOTIDE; DIPHTHERIA TOXOID; ENTEROTOXIN; GLYCOPROTEIN GP 160; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OLEIC ACID; RETINOIC ACID; TETANUS TOXOID; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADD ON THERAPY; ANTIGENICITY; CELL FREE SYSTEM; CELLULAR IMMUNITY; CLINICAL PROTOCOL; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EPIDERMIS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA; LYMPHOID TISSUE; MAJOR HISTOCOMPATIBILITY COMPLEX; MASS SPECTROMETRY; NON INVASIVE PROCEDURE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SKIN FUNCTION; VACCINATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; HUMANS; IMMUNITY, ACTIVE; IMMUNIZATION; RECEPTORS, LYMPHOCYTE HOMING; VACCINES;

EID: 33847625013     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2007.01.007     Document Type: Review

References (86)

1. Rappuoli R. From Pasteur to genomics: progress and challenges in infectious diseases. Nat Med 10 11 (2004) 1177-1185
2. Mora M., Veggi D., Santini L., Pizza M., and Rappuoli R. Reverse vaccinology. Drug Discov Today 8 10 (2003) 459-464
3. Akira S., Uematsu S., and Takeuchi O. Pathogen recognition and innate immunity. Cell 124 4 (2006) 783-801
4. Takeda K., Kaisho T., and Akira S. Toll-like receptors. Annu Rev Immunol 21 (2003) 335-376
5. Bynoe M.S., and Viret C. Antigen-induced suppressor T cells from the skin point of view: suppressor T cells induced through epicutaneous immunization. J Neuroimmunol 167 1-2 (2005) 4-12
6. Streilein J.W. Skin-associated lymphoid tissues (SALT): origins and functions. J Invest Dermatol 80 Suppl. (1983) 12s-16s
7. Bos J.D., and Meinardi M.M. The 500 Da rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 9 3 (2000) 165-169
8. Glenn G.M., Rao M., Matyas G.R., and Alving C.R. Skin immunization made possible by cholera toxin. Nature 391 6670 (1998) 851
9. Kahlon R., Hu Y., Orteu C.H., Kifayet A., Trudeau J.D., Tan R., et al. Optimization of epicutaneous immunization for the induction of CTL. Vaccine 21 21-22 (2003) 2890-2899
10. Klimuk S.K., Najar H.M., Semple S.C., Aslanian S., and Dutz J.P. Epicutaneous application of CpG oligodeoxynucleotides with peptide or protein antigen promotes the generation of CTL. J Invest Dermatol 122 4 (2004) 1042-1049
11. Dell K., Koesters R., and Gissmann L. Transcutaneous immunization in mice: induction of T-helper and cytotoxic T lymphocyte responses and protection against human papillomavirus-induced tumors. Int J Cancer 118 2 (2006) 364-372
12. Scharton-Kersten T., Yu J., Vassell R., O'Hagan D., Alving C.R., and Glenn G.M. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect Immun 68 9 (2000) 5306-5313
13. Tierney R., Beignon A.S., Rappuoli R., Muller S., Sesardic D., and Partidos C.D. Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses. J Infect Dis 188 5 (2003) 753-758
14. Seo N., Tokura Y., Nishijima T., Hashizume H., Furukawa F., and Takigawa M. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Proc Natl Acad Sci USA 97 1 (2000) 371-376
15. Yagi H., Hashizume H., Horibe T., Yoshinari Y., Hata M., Ohshima A., et al. Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous peptide immunization. Cancer Res 66 20 (2006) 10136-10144
16. Glenn G.M., Taylor D.N., Li X., Frankel S., Montemarano A., and Alving C.R. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med 6 12 (2000) 1403-1406
17. Belyakov I.M., Hammond S.A., Ahlers J.D., Glenn G.M., and Berzofsky J.A. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 113 7 (2004) 998-1007
18. Tezel A., Paliwal S., Shen Z., and Mitragotri S. Low-frequency ultrasound as a transcutaneous immunization adjuvant. Vaccine 23 29 (2005) 3800-3807
19. Zhao Y.L., Murthy S.N., Manjili M.H., Guan L.J., Sen A., and Hui S.W. Induction of cytotoxic T-lymphocytes by electroporation-enhanced needle-free skin immunization. Vaccine 24 9 (2006) 1282-1290
20. Rechtsteiner G., Warger T., Osterloh P., Schild H., and Radsak M.P. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol 174 5 (2005) 2476-2480
21. Mishra V., Mahor S., Rawat A., Dubey P., Gupta P.N., Singh P., et al. Development of novel fusogenic vesosomes for transcutaneous immunization. Vaccine 24 27-28 (2006) 5559-5570
22. Mishra D., Dubey V., Asthana A., Saraf D.K., and Jain N.K. Elastic liposomes mediated transcutaneous immunization against Hepatitis B. Vaccine 24 22 (2006) 4847-4855
23. Skountzou I., Quan F.S., Jacob J., Compans R.W., and Kang S.M. Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine 24 35-36 (2006) 6110-6119
24. Kim D.D., Kim J.L., and Chien Y.W. Mutual hairless rat skin permeation-enhancing effect of ethanol/water system and oleic acid. J Pharm Sci 85 11 (1996) 1191-1195
25. Fritsche J., Stonehouse T.J., Katz D.R., Andreesen R., and Kreutz M. Expression of retinoid receptors during human monocyte differentiation in vitro. Biochem Biophys Res Commun 270 1 (2000) 17-22
26. Ertesvag A., Engedal N., Naderi S., and Blomhoff H.K. Retinoic acid stimulates the cell cycle machinery in normal T cells: involvement of retinoic acid receptor-mediated IL-2 secretion. J Immunol 169 10 (2002) 5555-5563
27. Varani J., Zeigler M., Dame M.K., Kang S., Fisher G.J., Voorhees J.J., et al. Heparin-binding epidermal-growth-factor-like growth factor activation of keratinocyte ErbB receptors Mediates epidermal hyperplasia, a prominent side-effect of retinoid therapy. J Invest Dermatol 117 6 (2001) 1335-1341
28. Serruto D., and Rappuoli R. Post-genomic vaccine development. FEBS Lett 580 12 (2006) 2985-2992
29. Singh-Jasuja H., Emmerich N.P., and Rammensee H.G. The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol Immunother 53 3 (2004) 187-195
30. Stevanovic S. Identification of tumour-associated T-cell epitopes for vaccine development. Nat Rev Cancer 2 7 (2002) 514-520
31. Partidos C.D., Beignon A.S., Briand J.P., and Muller S. Modulation of immune responses with transcutaneously deliverable adjuvants. Vaccine 22 19 (2004) 2385-2390
32. Bourgeois C., and Tanchot C. Mini-review CD4 T cells are required for CD8 T cell memory generation. Eur J Immunol 33 12 (2003) 3225-3231
33. van der Burg S.H., Bijker M.S., Welters M.J., Offringa R., and Melief C.J. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. Adv Drug Deliv Rev 58 8 (2006) 916-930
34. Zwaveling S., Ferreira Mota S.C., Nouta J., Johnson M., Lipford G.B., Offringa R., et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 169 1 (2002) 350-358
35. Toes R.E., van der Voort E.I., Schoenberger S.P., Drijfhout J.W., van Bloois L., Storm G., et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol 160 9 (1998) 4449-4456
36. Spangler B.D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol Rev 56 4 (1992) 622-647
37. Anjuere F., George-Chandy A., Audant F., Rousseau D., Holmgren J., and Czerkinsky C. Transcutaneous immunization with cholera toxin B subunit adjuvant suppresses IgE antibody responses via selective induction of Th1 immune responses. J Immunol 170 3 (2003) 1586-1592
38. Baba T., Hanada K., and Hashimoto I. The study of ultraviolet B-induced apoptosis in cultured mouse keratinocytes and in mouse skin. J Dermatol Sci 12 1 (1996) 18-23
39. Bektas M., Orfanos C.E., and Geilen C.C. Different vitamin D analogues induce sphingomyelin hydrolysis and apoptosis in the human keratinocyte cell line HaCaT. Cell Mol Biol (Noisy-le-grand) 46 1 (2000) 111-119
40. Bektas M., Dullin Y., Wieder T., Kolter T., Sandhoff K., Brossmer R., et al. Induction of apoptosis by synthetic ceramide analogues in the human keratinocyte cell line HaCaT. Exp Dermatol 7 6 (1998) 342-349
41. Matsue H., Kobayashi H., Hosokawa T., Akitaya T., and Ohkawara A. Keratinocytes constitutively express the Fas antigen that mediates apoptosis in IFN gamma-treated cultured keratinocytes. Arch Dermatol Res 287 3-4 (1995) 315-320
42. + T cells. Immunology 105 2 (2002) 204-212
43. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3 2 (2002) 196-200
44. Itoh T., and Celis E. Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice. J Immunother 28 5 (2005) 430-437
45. Warger T., Osterloh P., Rechtsteiner G., Fassbender M., Heib V., Schmid B., et al. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 108 2 (2006) 544-550
46. Whitmore M.M., DeVeer M.J., Edling A., Oates R.K., Simons B., Lindner D., et al. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res 64 16 (2004) 5850-5860
47. Gautier G., Humbert M., Deauvieau F., Scuiller M., Hiscott J., Bates E.E., et al. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med 201 9 (2005) 1435-1446
48. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., and Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6 8 (2005) 769-776
49. Daynes R.A., Enioutina E.Y., Butler S., Mu H.H., McGee Z.A., and Araneo B.A. Induction of common mucosal immunity by hormonally immunomodulated peripheral immunization. Infect Immun 64 4 (1996) 1100-1109
50. Upadhyay P. Enhanced transdermal-immunization with diptheria-toxoid using local hyperthermia. Vaccine 24 27-28 (2006) 5593-5598
51. Enioutina E.Y., Visic D.M., and Daynes R.A. The induction of systemic and mucosal immunity to protein vaccines delivered through skin sites exposed to UVB. Vaccine 20 16 (2002) 2116-2130
52. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 6673 (1998) 245-252
53. Valladeau J., and Saeland S. Cutaneous dendritic cells. Semin Immunol 17 4 (2005) 273-283
54. Kissenpfennig A., Henri S., Dubois B., Laplace-Builhe C., Perrin P., Romani N., et al. Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 22 5 (2005) 643-654
55. Bennett C.L., van Rijn E., Jung S., Inaba K., Steinman R.M., Kapsenberg M.L., et al. Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J Cell Biol 169 4 (2005) 569-576
56. Kaplan D.H., Jenison M.C., Saeland S., Shlomchik W.D., and Shlomchik M.J. Epidermal langerhans cell-deficient mice develop enhanced contact hypersensitivity. Immunity 23 6 (2005) 611-620
57. Wollenberg A., Wagner M., Gunther S., Towarowski A., Tuma E., Moderer M., et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 119 5 (2002) 1096-1102
58. Urosevic M., Dummer R., Conrad C., Beyeler M., Laine E., Burg G., et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 97 15 (2005) 1143-1153
59. Palamara F., Meindl S., Holcmann M., Luhrs P., Stingl G., and Sibilia M. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 173 5 (2004) 3051-3061
60. Mitsui H., Watanabe T., Saeki H., Mori K., Fujita H., Tada Y., et al. Differential expression and function of Toll-like receptors in Langerhans cells: comparison with splenic dendritic cells. J Invest Dermatol 122 1 (2004) 95-102
61. Colonna M., Trinchieri G., and Liu Y.J. Plasmacytoid dendritic cells in immunity. Nat Immunol 5 12 (2004) 1219-1226
62. Stoitzner P., Tripp C.H., Eberhart A., Price K.M., Jung J.Y., Bursch L., et al. Langerhans cells cross-present antigen derived from skin. Proc Natl Acad Sci USA 103 20 (2006) 7783-7788
63. Carbone F.R., Belz G.T., and Heath W.R. Transfer of antigen between migrating and lymph node-resident DCs in peripheral T-cell tolerance and immunity. Trends Immunol 25 12 (2004) 655-658
64. de Jong E.C., Smits H.H., and Kapsenberg M.L. Dendritic cell-mediated T cell polarization. Springer Semin Immunopathol 26 3 (2005) 289-307
65. Wing K., Fehervari Z., and Sakaguchi S. Emerging possibilities in the development and function of regulatory T cells. Int Immunol 18 7 (2006) 991-1000
66. high regulatory T cells modulate myeloid but not plasmacytoid dendritic cells activation. J Immunol 176 9 (2006) 5293-5298
67. Flacher V., Bouschbacher M., Verronese E., Massacrier C., Sisirak V., Berthier-Vergnes O., et al. Human Langerhans cells express a specific TLR profile and differentially respond to viruses and gram-positive bacteria. J Immunol 177 11 (2006) 7959-7967
68. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 10 (2004) 987-995
69. Suzuki H., Wang B., Shivji G.M., Toto P., Amerio P., Tomai M.A., et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 114 1 (2000) 135-141
70. Mempel M., Voelcker V., Kollisch G., Plank C., Rad R., Gerhard M., et al. Toll-like receptor expression in human keratinocytes: nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. J Invest Dermatol 121 6 (2003) 1389-1396
71. Lebre M.C., van der Aar A.M., van Baarsen L., van Capel T.M., Schuitemaker J.H., Kapsenberg M.L., et al. Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J Invest Dermatol 127 2 (2007) 331-341
72. Kollisch G., Kalali B.N., Voelcker V., Wallich R., Behrendt H., Ring J., et al. Various members of the Toll-like receptor family contribute to the innate immune response of human epidermal keratinocytes. Immunology 114 4 (2005) 531-541
73. Uchi H., Terao H., Koga T., and Furue M. Cytokines and chemokines in the epidermis. J Dermatol Sci 24 Suppl. 1 (2000) S29-S38
74. Grone A. Keratinocytes and cytokines. Vet Immunol Immunopathol 88 1-2 (2002) 1-12
75. Kono T., Kondo S., Pastore S., Shivji G.M., Tomai M.A., McKenzie R.C., et al. Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. Lymphokine Cytokine Res 13 2 (1994) 71-76
76. Inoue J., and Aramaki Y. Toll-like receptor-9 expression induced by tape-stripping triggers on effective immune response with CpG-oligodeoxynucleotides. Vaccine 25 6 (2007) 1007-1013
77. + T regulatory cells and is dependent on host-derived IL-10. J Immunol 176 4 (2006) 2635-2644
78. + T cell-mediated suppression by dendritic cells. Science 299 5609 (2003) 1033-1036
79. Agace W.W. Tissue-tropic effector T cells: generation and targeting opportunities. Nat Rev Immunol 6 9 (2006) 682-692
80. Dudda J.C., Lembo A., Bachtanian E., Huehn J., Siewert C., Hamann A., et al. Dendritic cells govern induction and reprogramming of polarized tissue-selective homing receptor patterns of T cells: important roles for soluble factors and tissue microenvironments. Eur J Immunol 35 4 (2005) 1056-1065
81. Calzascia T., Masson F., Berardino-Besson W., Contassot E., Wilmotte R., Aurrand-Lions M., et al. Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 22 2 (2005) 175-184
82. Enioutina E.Y., Visic D., and Daynes R.A. The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity. Vaccine 18 24 (2000) 2753-2767
83. Pior J., Vogl T., Sorg C., and MacHer E. Free hapten molecules are dispersed by way of the bloodstream during contact sensitization to fluorescein isothiocyanate. J Invest Dermatol 113 6 (1999) 888-893
84. Guerena-Burgueno F., Hall E.R., Taylor D.N., Cassels F.J., Scott D.A., Wolf M.K., et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immun 70 4 (2002) 1874-1880
85. Frech S.A., Kenney R.T., Spyr C.A., Lazar H., Viret J.F., Herzog C., et al. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. Vaccine 23 7 (2005) 946-950
86. Warger T, et al. Clin Rev Allergy Immunol, in press.